Jun 12, 2008|
RBI's move, stock's groove & more
Fed talks it, RBI does itOur view on RBI's monetary policy for FY09
In its late yesterday move, the Reserve Bank of India (RBI) has raised its key lending rate - repo rate, the rate at which it lends to banks - by 0.25% to 8%. This move comes in the wake of rising pressure on the central bank to rein in inflation, currently ruling at its 4-year high of over 8.2% (based on the wholesale price index). After a series of CRR (cash reserve ratio) hikes over the past few months, the latest measure is expected to further dampen credit demand in the country.
This repo rate hike is likely to add to the worries of bankers who are finding it difficult to pass on the already prevailing high interest rates to customers for the fear of dissuading them in payment of their EMIs (equated monthly installments) or availing fresh loans. Inability to exercise their pricing power on incremental loans will inadvertently shave some margins off the banks' books. This comes at a time when credit offtake has seen some slowdown while NPA (non-performing assets) levels are on a rise.
However, Mr. Deepak Parekh, the Chairman and Managing Director of HDFC and one of the leading veterans from the Indian financial sector, has a different opinion to offer. According to him, a hike of 0.5% to 1.0% in interest rates will not hurt the customer's monthly payments significantly and thus not hurt the consumer spending or the economic growth. While this may hold true in the case home loans, particularly those with small ticket sizes and acquired for residential purposes, loans on auto, consumer durables and credit cards are already losing favour. The latest move from the RBI is indeed a brave step from the central bank while its peer, the US Federal Reserve, has just started hinting towards rate increase in the world's largest economy.
What is the Fed saying?
Indian Pharma's latest themeRead our initial views on the deal
India's largest pharmaceutical company, Ranbaxy, which in the past two years, has been on the prowl to acquire companies and has actually made a string of acquisitions now finds itself on the other side of the table. The company announced today that its promoters namely Malvinder Singh and Shivinder Singh would sell their entire stake (around 35%) to the Japanese pharma company Daiichi Sankyo at a price of Rs 737 per share.
The transaction is valued at US$ 3.4 bn to US$ 4.6 bn and Ranbaxy overall at US$ 8.5 bn. Considering the fact that Ranbaxy generated revenues to the tune of US$ 1.7 bn in CY07, this implies a price to sales ratio of around 5 times, which is by no means cheap for Daiichi. This development further brings to fore the expensive valuations that are prevailing in pharmaceutical mergers in the global generics space. As per SEBI regulations, Daiichi will make an open offer to the public shareholders to purchase additional 20% shareholding, thereby taking its total stake in Ranbaxy to around 55%. With Dabur Pharma's promoters cashing out recently (by selling their 73% stake to a Singapore firm), promoters selling stakes seem to be another theme brewing in the India pharma space. Whether this will be detrimental to the interests of minority shareholders remains to be seen. Watch out this space for more on the same.
Haze surrounding stocksRoadblock that's hit Asian stocks
There is a haze surrounding the Bombay Stock Exchange building, as seen from our office window. While this haze is on account of Mumbai's unrelenting monsoon showers, there is another haze that surrounds stocks listed on the exchange, or for that matter stocks listed in India, and Hong Kong, and China, and the US. Economic growth worries fueled by higher oil prices, rising inflation and subsequently lower consumption spending has severely impacted sentiments across the world. In today's trade, for instance, all major Asian markets are trading deep in the red, with Japan, China and Hong Kong down by 2.5% apiece. The US markets closed yesterday at its lowest levels since March. This followed a spike of US$ 5 in crude oil price, as it rose to US$ 136.4 per barrel.
Vibes coming out of the US Federal Reserve, which suggest that the central bank of the world's largest economy is planning to target inflation (thereby indicating higher interest rates going forward) have also playe
d spoilsport for the Asian indices. How does the Indian markets react remains to be seen.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 16, 2017
All across the country, the old gods become devils. New, gluten-free gods take their places...
Aug 16, 2017
And what it has in common with beating the stock market too.
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Aug 14, 2017
Last week's correction is making a number of Super Investor stocks look a lot more attractive...
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 4, 2017
The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407